ArticleCancer research2008
DNA damage signaling in hematopoietic cells: a role for Mre11 complex repair of topoisomerase lesions.
Article in Cancer research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 17 citations in OpenAlex.
- DNA damage and repair in the hematopoietic system.Acta biochimica et biophysica Sinica · 2022Review
- Nbs1-mediated DNA damage repair pathway regulates haematopoietic stem cell development and embryonic haematopoiesis.Cell proliferation · 2021Article
- Topoisomerase I (Top1): a major target of FL118 for its antitumor efficacy or mainly involved in its side effects of hematopoietic toxicity?American journal of cancer research · 2017Article
- Generation of a novel, multi-stage, progressive, and transplantable model of plasma cell neoplasms.Scientific reports · 2016Article
- Interdependence of the rad50 hook and globular domain functions.Molecular cell · 2015Article
- The Rad50 hook domain regulates DNA damage signaling and tumorigenesis.Genes & development · 2014Article
- Loss of aryl hydrocarbon receptor promotes gene changes associated with premature hematopoietic stem cell exhaustion and development of a myeloproliferative disorder in aging mice.Stem cells and development · 2014Article
- Myelodysplastic syndrome: an inability to appropriately respond to damaged DNA?Experimental hematology · 2013Review
- MRE11 facilitates the removal of human topoisomerase II complexes from genomic DNA.Biology open · 2012Article
- Functional interplay of the Mre11 nuclease and Ku in the response to replication-associated DNA damage.Molecular and cellular biology · 2011Article
- The mef/elf4 transcription factor fine tunes the DNA damage response.Cancer research · 2011Article
- The MRE11 complex: starting from the ends.Nature reviews. Molecular cell biology · 2011Review
- Mutation of NIMA-related kinase 1 (NEK1) leads to chromosome instability.Molecular cancer · 2011Article
- Making the best of the loose ends: Mre11/Rad50 complexes and Sae2 promote DNA double-strand break resection.DNA repair · 2010Review
- The p53 tumor suppressor protein is a critical regulator of hematopoietic stem cell behavior.Cell cycle (Georgetown, Tex.) · 2009Review
- Rad50 is dispensable for the maintenance and viability of postmitotic tissues.Molecular and cellular biology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
The Mre11 complex promotes DNA double-strand break repair and regulates DNA damage signaling via activation of the ataxia-telangiectasia mutated (ATM) kinase. The hypermorphic Rad50(S) allele encodes a variant of Rad50, a member of the Mre11 complex. Cells expressing Rad50(S) experience constitutive ATM activation, which leads to precipitous apoptotic attrition in hematopoietic cells. In this study, we show that ATM activation by the Rad50S-containing Mre11 complex enhances the proliferation of LSK cells, a population consisting of hematopoietic stem cells and multipotent progenitor cells. In Rad50(S/S) mice, enhanced LSK proliferation triggers apoptotic attrition. This phenotype is mitigated when Rad50(S/S) is combined with mutations that alter either LSK cell quiescence (myeloid elf-1-like factor/ELF4-deficient mice) or hematopoietic differentiation (p21- and p27-deficient mice), indicating that the LSK population is a primary target of Rad50(S) pathology. We show that cells from Rad50(S/S) mice are hypersensitive to camptothecin, a topoisomerase I inhibitor that causes DNA damage primarily during DNA replication. On this basis, we propose that apoptotic attrition of Rad50(S/S) hematopoietic cells results from enhanced proliferation in the context of topoisomerase-associated DNA damage. Impairment of apoptosis in Rad50(S/S) mice promotes hematopoietic malignancy, suggesting that primitive hematopoietic cells serve as a reservoir of potentially oncogenic lesions in Rad50(S/S) mice. These data provide compelling evidence that the Mre11 complex plays a role in the metabolism of topoisomerase lesions in mammals, and further suggest that such lesions can accumulate in primitive hematopoietic cells and confer significant oncogenic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.